Ruthia He, whose company was the subject of a Wall Street Journal investigation, was accused of orchestrating a scheme to profit from Adderall prescriptions.
Source link
Ruthia He, whose company was the subject of a Wall Street Journal investigation, was accused of orchestrating a scheme to profit from Adderall prescriptions.
Source link